PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Positive surgical margins after radical prostatectomy. Part II
Article published in Urologia Polska 2006/59/2.

authors

Andrzej Borówka 1, Jakub Dobruch 1, Tomasz Dzik 2, Przemysław Szostek 1, Artur A. Antoniewicz 1, Piotr Chłosta 3
1 Klinika Urologii Centrum Medycznego Kształcenia Podyplomowego, I Zespół Dydaktyki Urologicznej - Oddział Urologii Międzyleskiego Szpitala Specjalistycznego w Warszawie
2 Zakład Patomorfologii Międzyleskiego Szpitala Specjalistycznego w Warszawie
3 Dział Urologii Świętokrzyskiego Centrum Onkologii w Kielcach

keywords

prostate, prostate cancer, positive surgical margins

summary

Radical prostatectomy is a fundamental way of treatment of clinically organ confined prostate cancer. Presence of cancer cells within ink-stained specimen surface is defined as positive surgical margin (PSM). The relation between their presence and PSA, Gleason score, neoadjuvant hormonal therapy or tumor volume is widely known. Positive surgical margins are negative prognostic markers which require modification of further treatment.
In the present paper clinical significance of positive surgical margins found after radical prostatectomy and way of treatment of patients with PSM are presented.

references

  1. van den Ouden D, Bentvelsen FM, Boeve ER et al: Positive margins after radical prostatectomy: correlation with local recurrence and distant progression. Brit J Urol 1993, 72, 489-494.
  2. Watson RB, Civantos F, Soloway MS: Positive surgical margins with radical prostatectomy: detailed pathological analysis and prognosis. Urology 1996, 48, 80-90.
  3. Weldon VE, Tavel FR, Neuwirth H et al: Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J Urol 1995, 153, 1565-1569.
  4. Paulson DF: Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994, 152, 1826-1830.
  5. Smith RC, Partin AW, Epstein JI, Brendler CB: Extended follow up of the influence of wide excision of the neurovascular bundle (s) on prognosis in men with clinically localized prostate cancer and extensive capsular perforation. J Urol 1996, 156, 454-458.
  6. Epstein JI, Partin AW, Sauvageot J, Walsh PC: Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996, 20, 286-292.
  7. Paulson DF, Moul JW, Walther PJ: Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol 1990, 144, 1180-1184.
  8. Paulson DF: Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994, 152, 1826-1830.
  9. Stamey TA, Yang N, Hay AR et al: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 317, 909-916.
  10. Oesterling JE, Chan DW, Epstein JI et al: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988, 139, 766-772.
  11. McCarthy JF, Catalona WJ, Hudson MA: Effect of radiation therapy on detectable serum, prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. J Urol 1994, 151, 1575-1578.
  12. Lange PH, Lightner DJ, Medini E et al: The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. J Urol 1990, 144, 927-933.
  13. Gibbons RP, Cole BS, Richardson RG et al: Adjuvant radiotherapy following radical prostatectomy: results and complications. J Urol 1986, 135, 65-68.
  14. Eisbruch A, Perez CA, Roessler EH, Lockett MA: Adjuvant irradiation after prostatectomy for carcinoma of the prostate with positive surgical margins. Cancer 1994, 73, 384-388.
  15. Carter GE, Lieskovsky G, Skinner DG, Petrovich Z: Results of local and/or systemic adjuvant therapy in the management of pathological stage C or D1 prostate cancer following radical prostatectomy. J Urol 1989, 142, 1266-1270.
  16. Meier R, Mark R, St. Royal L et al: Postoperative radiation therapy after radical prostatectomy for prostate carcinoma. Cancer 1992, 70, 1960-1966.
  17. Partin AW, Oesterling JE: The clinical usefulness of prostate specific antigen: update 1994. J Urol, 1994, 15, 1358-1368.
  18. Patel A, Dorey F, Franklin J, de Kernion JB: Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of PSA doubling times and log slope PSA. J Urol 1997, 158, 1441-1445.
  19. Pound CR, Partin AW, Epstein JI et al: Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin N Am 1997, 24, 395-406.
  20. Petrovich Z, Lieskovsky G, Langholz B et al: Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 2002, 53, 600-609.
  21. Takayama TK, Lange PH: Radiation therapy for local recurrence of prostate cancer after radical prostatectomy. Urol Clin N Amer 1994, 21, 687-700.
  22. Cheng WS, Frydenberg M, Bergstralh EJ et al: Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology 1993, 42, 283-291.
  23. Tyrrell CJ, Payne H, See WA et al: Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol 2005, 76, 4-10.
  24. Wirth M, Tyrrell C, Delaere K et al: Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. Prostate Cancer Prostatic Dis 2005, 8, 194-200.
  25. Andriole G, Lieber M, Smith J et al: Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 1995, 45, 491-497.
  26. Remzi M, Waldert M, Djavan B: Preoperative nomograms and artificial neural networks (ANNs) for identification of surgical candidates. EAU Update Series 2005, 3, 63-71.
  27. Wieder JA, Soloway MS: Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol 1998, 160, 299-315.

correspondence

Jakub Dobruch
Międzyleski Szpital Specjalistyczny
ul. Bursztynowa 2
04-749 Warszawa
tel. 0 503 072 230
kubadobr@wp.pl